[18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour Abstract #1381

Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Aim(s): To evaluate the correlation between FP and response to chemotherapy (CHT) and everolimus (E) for pancreatic NETs (PanNETs).
Materials and methods: Baseline and post-treatment imaging studies (contrast enhanced CT/MRI and FP) of 31 patients (P) treated for advanced, G1-2 PanNETs were retrospectively reviewed. A per lesion analysis was conducted, separately for each treatment arm (CHT and E), selecting up to 6 lesions (L) for each P. Baseline FP results (positive if SUV max > 3.5) and RECIST1.1 disease control rate (DCR) and objective response rate (ORR) were analyzed for possible correlations.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani

To read results and conclusion, please login ...

Further abstracts you may be interested in

#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#253 Description and Treatment of GEP NETs in a Spanish Hospital During 10 Years
Introduction: In our area the GEP NET incidence is similar to that of gastric and exocrine pancreatic cancers consequently being important to know their characteristics and the most convenient therapeutic approach.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#465 Management of an Advanced Pancreatic Neuroendocrine Tumor
Introduction: Whereas an array of treatment modalities have evolved for management of pancreatic NETs, there has been a lack of information regarding a clear algorithm of optimal treatment or an appropriate sequence in which different treatment modalities can be applied to a given patient for optimal results.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, Al-Hindi H, ...
#732 Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: dr Sara Pusceddu
Keywords: everolimus
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi